المؤلفون: A. L. Kornietskaya, S. F. Evdokimova, L. V. Bolotina, A. A. Fedenko, А. Л. Корниецкая, С. Ф. Евдокимова, Л. В. Болотина, А. А. Феденко

المصدر: Meditsinskiy sovet = Medical Council; № 10 (2024); 145-150 ; Медицинский Совет; № 10 (2024); 145-150 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: клинический случай, esophagogastric junction cancer, trastuzumab deruxtecan, chemotherapy, HER2-neu, trastuzumab resistance, case report, кардиоэзофагеальный переход, трастузумаб дерукстекан, химиотерапия, резистентность к трастузумабу

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8406/7397; Каприн АД (ред.). Злокачественные новообразования в России в 2022 году. М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2023. Режим доступа: https://oms66.ru/upload/iblock/52d/6u9uo6ajmjooxfl8m738lck2qzog7lza/zno_2022.pdf.; Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. https://doi.org/10.3322/caac.21660.; Hofmann M, Stoss O, Shi D, Büttner R, Van De Vijver M, Kim W et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797–805. https://doi.org/10.1111/j.1365-2559.2008.03028.x.; Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer THERapy. Chem Pharm Bull (Tokyo). 2019;67:173–185. https://doi.org/10.1248/cpb.c18-00744.; Gao X, Zhao L, Zhang N, Han W, Liu K, Yan J et al. Impact of HER2 on prognosis and benefit from adjuvant chemotHERapy in stage II/III gastric cancer patients: a multicenter observational study. Int J Surg Lond Engl. 2023;109:1330–1341. https://doi.org/10.1097/JS9.0000000000000370.; Motoshima S, Yonemoto K, Kamei H, Morita M, Yamaguchi R. Prognostic implications of HER2 heterogeneity in gastric cancer. Oncotarget. 2018;9(10):9262–9272. https://doi.org/10.18632/oncotarget.24265.; Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al. Trastuzumab in combination with chemotHERapy versus chemotHERapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet. 2010;376:687–697. https://doi.org/10.1016/S0140-6736(10)61121-X.; Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017;18(5):640–653. https://doi.org/10.1016/S1470-2045(17)30111-0.; Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K et al. Pertuzumab plus trastuzumab and chemotHERapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a doubleblind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018;19:1372–1384. https://doi.org/10.1016/S1470-2045(18)30481-9.; Satoh T, Xu R-H, Chung HC, Sun G-P, Doi T, Xu J-M et al. Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2Amplified Advanced Gastric Cancer in Asian Populations: TyTAN – A Randomized, Phase III Study. J Clin Oncol. 2014;32(19):2039–2049. https://doi.org/10.1200/JCO.2013.53.6136.; Hecht JR, Bang Y-J, Qin SK, Chung HC, Xu JM, Park JO et al. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC-A Randomized Phase III Trial. J Clin Oncol. 2016;34:443–451. https://doi.org/10.1200/JCO.2015.62.6598.; Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J et al. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. N Engl J Med. 2012;367(19):1783–1791. https://doi.org/10.1056/NEJMoa1209124.; Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387(1):9–20. https://doi.org/10.1056/NEJMoa2203690.; Hurvitz SA, Hegg R, Chung W-P, Im S-A, Jacot W, Ganju V et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. The Lancet. 2023;401(10371):105–117. https://doi.org/10.1016/S0140-6736(22)02420-5.; Shitara K, Bang Y-J, Iwasa S, Sugimoto N, Ryu M-H, Sakai D et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020;382(25):2419–2430. https://doi.org/10.1056/NEJMoa2004413.; Le DT, Ott PA, Korytowsky B, Le H, Le TK, Zhang Y et al. Real-world Treatment Patterns and Clinical Outcomes Across Lines of THERapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. Clin Colorectal Cancer. 2020;19(1):32-38.e3. https://doi.org/10.1016/j.clcc.2019.09.001.; Seo S, Ryu M-H, Park YS, Ahn JY, Park Y, Park SR et al. Loss of HER2 positivity after anti-HER2 chemotHERapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3). Gastric Cancer. 2019;22(3):527–535. https://doi.org/10.1007/s10120-018-0891-1.; https://www.med-sovet.pro/jour/article/view/8406

الاتاحة: https://www.med-sovet.pro/jour/article/view/8406
https://doi.org/10.21518/ms2024-250